William Blair upgraded Larimar Therapeutics (NASDAQ:LRMR) to “outperform” after the FDA approved the company’s proposed Phase 2 study design for CTI-1601 in Friedreich’s ataxia (FA), enabling a return to clinical...
William Blair initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with an “outperform” rating and fair value estimate of $29. The stock closed at $15.44 on Jan. 29. Larimar is developing intracellular-targeted...